Dino Sgarabotto
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Dino Sgarabotto has a total of 238 co-authors. Here are the top co-authors by number of shared publications:
- Fabrizio Vianello
Hematology Unit, Department of Medicine–DIMED, University-Hospital of Padua, Padua, Italy
13 shared publications A Girolami
7 shared publicationsGiorgio Palù
Microbiology and Virology Unit, Padova University Hospital, Padova, Italy
7 shared publications- Francesco Dazzi
School of Cardiovascular and Metabolic Medicine & Sciences, King’s College London
6 shared publications Riccardo Cusinato
Department of Molecular Medicine, Padua General Hospital, University of Padua School of Medicine, Padua, Italy
6 shared publicationsAntonio Girolami
5 shared publications
Latest Publications
- 4 July 2017
- Vol. 40 (4) , 291-294
Plasmodium knowlesi malaria in a traveller returning from the Philippines to Italy, 2016.
Plasmodium knowlesi is a simian parasite responsible for most human cases of malaria in Malaysian Borneo. A timely recognition of infection is crucial because of the risk of severe disease due to the rapid increase in parasitemia. We report a case of P. knowlesi infection in a traveller who developed fever and thrombocytopenia after returning from the Philippines in 2016. Rapid antigen test was negative, microscopy examination showed parasites similar to Plasmodium malariae, with a parasite count of 10,000 parasites per μL blood, while molecular testing identified P. knowlesi infection. Treatment with atovaquone-proguanil led to resolution of fever and restoration of platelet count in two days. P. knowlesi infection should be suspected in febrile travellers returning from South East Asia. Due to the low sensitivity of rapid antigen tests and the low specificity of microscopy, confirmation by molecular tests is recommended.
- 4 July 2017
- Vol. 40 (4) , 291-294
Plasmodium knowlesi malaria in a traveller returning from the Philippines to Italy, 2016.
Plasmodium knowlesi is a simian parasite responsible for most human cases of malaria in Malaysian Borneo. A timely recognition of infection is crucial because of the risk of severe disease due to the rapid increase in parasitemia. We report a case of P. knowlesi infection in a traveller who developed fever and thrombocytopenia after returning from the Philippines in 2016. Rapid antigen test was negative, microscopy examination showed parasites similar to Plasmodium malariae, with a parasite count of 10,000 parasites per μL blood, while molecular testing identified P. knowlesi infection. Treatment with atovaquone-proguanil led to resolution of fever and restoration of platelet count in two days. P. knowlesi infection should be suspected in febrile travellers returning from South East Asia. Due to the low sensitivity of rapid antigen tests and the low specificity of microscopy, confirmation by molecular tests is recommended.
- 2 May 2017
- Published by Frontiers Media SA in Transplant International
- Vol. 30 (7) , 734-736
Antibiotic prophylaxis for preventing postorthotopic liver transplant tuberculosis: is there a safe alternative to isoniazid?
- 2 May 2017
- Published by Frontiers Media SA in Transplant International
- Vol. 30 (7) , 734-736
Antibiotic prophylaxis for preventing postorthotopic liver transplant tuberculosis: is there a safe alternative to isoniazid?
- 1 May 2017
- Published by Elsevier in Transplantation Proceedings
- Vol. 49 (4) , 736-739
Liver Retransplantation for Hepatic Abscess Due to Hepatic Artery Thrombosis: A Case Report
- 1 May 2017
- Published by Elsevier in Transplantation Proceedings
- Vol. 49 (4) , 736-739
Liver Retransplantation for Hepatic Abscess Due to Hepatic Artery Thrombosis: A Case Report
- Open Access
- 11 August 2016
- Published by European Centre for Disease Control and Prevention (ECDC) in Eurosurveillance
- Vol. 21 (32)
Infection dynamics in a traveller with persistent shedding of Zika virus RNA in semen for six months after returning from Haiti to Italy, January 2016
We describe the dynamics of Zika virus (ZIKV) infection in a man in his early 40s who developed fever and rash after returning from Haiti to Italy, in January 2016. Follow-up laboratory testing demonstrated detectable ZIKV RNA in plasma up to day 9 after symptom onset and in urine and saliva up to days 15 and 47, respectively. Notably, persistent shedding of ZIKV RNA was demonstrated in semen, still detectable at 181 days after onset.
- 11 August 2016
- Published by European Centre for Disease Control and Prevention (ECDC) in Eurosurveillance
- Vol. 21 (32)
Open AccessInfection dynamics in a traveller with persistent shedding of Zika virus RNA in semen for six months after returning from Haiti to Italy, January 2016
We describe the dynamics of Zika virus (ZIKV) infection in a man in his early 40s who developed fever and rash after returning from Haiti to Italy, in January 2016. Follow-up laboratory testing demonstrated detectable ZIKV RNA in plasma up to day 9 after symptom onset and in urine and saliva up to days 15 and 47, respectively. Notably, persistent shedding of ZIKV RNA was demonstrated in semen, still detectable at 181 days after onset.
- Open Access
- 30 May 2016
- Published by Frontiers Media SA in Transplant International
- Vol. 29 (9) , 1053-1054
Nebulized liposomal amphotericin prophylaxis in lung transplantation: shall we take it or leave it?
Evaluation of the efficacy of prophylactic\ud nebulized amphotericin B lipid complex (nABLC) in lung transplantation at our University Hospita
- 30 May 2016
- Published by Frontiers Media SA in Transplant International
- Vol. 29 (9) , 1053-1054
Open AccessNebulized liposomal amphotericin prophylaxis in lung transplantation: shall we take it or leave it?
Evaluation of the efficacy of prophylactic\ud nebulized amphotericin B lipid complex (nABLC) in lung transplantation at our University Hospita
- Open Access
- 8 January 2016
- Published by Elsevier in American Journal of Transplantation
- Vol. 16 (7) , 2016-2029
Cell Therapy for Parkinson’s Disease: A Translational Approach to Assess the Role of Local and Systemic Immunosuppression
- 8 January 2016
- Published by Elsevier in American Journal of Transplantation
- Vol. 16 (7) , 2016-2029
Open AccessCell Therapy for Parkinson’s Disease: A Translational Approach to Assess the Role of Local and Systemic Immunosuppression
- 1 September 2014
- Published by Elsevier in Clinical Microbiology and Infection
- Vol. 20, 19-26
Cytomegalovirus infection in solid organ transplant recipients
- 1 September 2014
- Published by Elsevier in Clinical Microbiology and Infection
- Vol. 20, 19-26
Cytomegalovirus infection in solid organ transplant recipients
- Open Access
- 1 March 2014
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 52 (3) , 1025
Comparison of Cytomegalovirus (CMV) Enzyme-Linked Immunosorbent Spot and CMV Quantiferon Gamma Interferon-Releasing Assays in Assessing Risk of CMV Infection in Kidney Transplant Recipients
- 1 March 2014
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 52 (3) , 1025
Open AccessComparison of Cytomegalovirus (CMV) Enzyme-Linked Immunosorbent Spot and CMV Quantiferon Gamma Interferon-Releasing Assays in Assessing Risk of CMV Infection in Kidney Transplant Recipients
- 26 November 2013
- Published by Springer Nature in Infection
- Vol. 42 (2) , 335-342
Tuberculosis of the eye in Italy: a forgotten extrapulmonary localization
Tuberculosis (TB) of the eye is a well-known extrapulmonary localization in high-incidence countries. Data on its relevance in developed countries are scanty. We aim to study the epidemiological and clinical pattern of ocular TB in a tertiary care institution of a western country. From 2007 to 2010, consecutive patients with a diagnosis of isolated ocular TB or associated to extraocular TB were recruited. Patients with ophthalmological and clinical features of TB were treated with standard antitubercular therapy (ATT) and steroids in case of concomitant severe ocular inflammation. Seventeen cases of ocular and extraocular TB and 45 cases of isolated ocular TB were identified. The proportion of patients with ocular and extraocular TB in our local district was 8.1 %, with a proportion of 10.6 % for the isolated cases. In Cohort 1, only one patient was symptomatic for ocular impairment, and uveitis without inflammation was the most common presentation. On the contrary, in Cohort 2, all patients had visual impairment, mainly with bilateral involvement. 77.8 % of the patients showed an inflammatory pattern. ATT was administered for at least 9 months, in four cases with a short course of systemic corticosteroids. Eight cases in Cohort 2 showed recurrence after 1 year from diagnosis. TB of the eye should not be forgotten, even in geographical areas not considered among endemic countries. Ocular evaluation is advisable in patients with pulmonary and extrapulmonary TB, as early detection may allow ATT to preserve visual acuity.
- 26 November 2013
- Published by Springer Nature in Infection
- Vol. 42 (2) , 335-342
Tuberculosis of the eye in Italy: a forgotten extrapulmonary localization
Tuberculosis (TB) of the eye is a well-known extrapulmonary localization in high-incidence countries. Data on its relevance in developed countries are scanty. We aim to study the epidemiological and clinical pattern of ocular TB in a tertiary care institution of a western country. From 2007 to 2010, consecutive patients with a diagnosis of isolated ocular TB or associated to extraocular TB were recruited. Patients with ophthalmological and clinical features of TB were treated with standard antitubercular therapy (ATT) and steroids in case of concomitant severe ocular inflammation. Seventeen cases of ocular and extraocular TB and 45 cases of isolated ocular TB were identified. The proportion of patients with ocular and extraocular TB in our local district was 8.1 %, with a proportion of 10.6 % for the isolated cases. In Cohort 1, only one patient was symptomatic for ocular impairment, and uveitis without inflammation was the most common presentation. On the contrary, in Cohort 2, all patients had visual impairment, mainly with bilateral involvement. 77.8 % of the patients showed an inflammatory pattern. ATT was administered for at least 9 months, in four cases with a short course of systemic corticosteroids. Eight cases in Cohort 2 showed recurrence after 1 year from diagnosis. TB of the eye should not be forgotten, even in geographical areas not considered among endemic countries. Ocular evaluation is advisable in patients with pulmonary and extrapulmonary TB, as early detection may allow ATT to preserve visual acuity.
- Open Access
- 1 August 2013
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 51 (8) , 2501-2507
Comparison of Cytomegalovirus (CMV) Enzyme-Linked Immunosorbent Spot and CMV Quantiferon Gamma Interferon-Releasing Assays in Assessing Risk of CMV Infection in Kidney Transplant Recipients
Assessing cytomegalovirus (CMV)-specific cell-mediated immunity (CMI) represents an appealing strategy for identifying transplant recipients at risk of infection. In this study, we compared two gamma interferon-releasing assays (IGRAs), Quantiferon-CMV and CMV enzyme-linked immunosorbent spot (ELISPOT), to determine the ability of each test to predict protective CMV-specific T-cell responses. Two hundred twenty-one Quantiferon-CMV and ELISPOT tests were conducted on 120 adult kidney transplant recipients (KTRs), including 100 CMV-seropositive transplant recipients (R + ) and 20 CMV-seronegative transplant recipients of a CMV-positive donor (D + /R − ). As a control cohort, 39 healthy adult subjects (including 33 CMV-seropositive and 6 CMV-seronegative subjects) were enrolled. CMV IgG serology was used as a reference for both tests. In the CMV-seropositive individuals, the ELISPOT and Quantiferon-CMV assays provided 46% concordance with the serology, 12% discordance, 18% disagreement between ELISPOT or Quantiferon-CMV and the serology, and 24% gray areas when one or both tests resulted in weak positives. None of the CMV-seronegative subjects showed detectable responses in the ELISPOT or the Quantiferon-CMV test. In transplant recipients, both the ELISPOT and Quantiferon-CMV assays positively correlated with each other and negatively correlated with CMV DNAemia in a significant way ( P < 0.05). During the antiviral prophylaxis, all 20 D + /R − KTRs we examined displayed undetectable Quantiferon-CMV and ELISPOT results, and there was no evidence of CMV seroconversion. The receiving operator curve (ROC) statistical analysis revealed similar specificities and sensitivities in predicting detectable viremia (areas under the curve [AUC], 0.66 and 0.62 for Quantiferon-CMV and ELISPOT, respectively). ELISPOT and Quantiferon-CMV values of >150 spots/200,000 peripheral blood mononuclear cells (PBMCs) and >1 to 6 IU gamma interferon (IFN-γ) were associated with protection from CMV infection (odds ratios [OR], 5 and 8.75, respectively). In transplant recipients, the two tests displayed similar abilities for predicting CMV infection. Both the ELISPOT and Quantiferon-CMV assays require several ameliorations to avoid false-negative results.
- 1 August 2013
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 51 (8) , 2501-2507
Open AccessComparison of Cytomegalovirus (CMV) Enzyme-Linked Immunosorbent Spot and CMV Quantiferon Gamma Interferon-Releasing Assays in Assessing Risk of CMV Infection in Kidney Transplant Recipients
Assessing cytomegalovirus (CMV)-specific cell-mediated immunity (CMI) represents an appealing strategy for identifying transplant recipients at risk of infection. In this study, we compared two gamma interferon-releasing assays (IGRAs), Quantiferon-CMV and CMV enzyme-linked immunosorbent spot (ELISPOT), to determine the ability of each test to predict protective CMV-specific T-cell responses. Two hundred twenty-one Quantiferon-CMV and ELISPOT tests were conducted on 120 adult kidney transplant recipients (KTRs), including 100 CMV-seropositive transplant recipients (R + ) and 20 CMV-seronegative transplant recipients of a CMV-positive donor (D + /R − ). As a control cohort, 39 healthy adult subjects (including 33 CMV-seropositive and 6 CMV-seronegative subjects) were enrolled. CMV IgG serology was used as a reference for both tests. In the CMV-seropositive individuals, the ELISPOT and Quantiferon-CMV assays provided 46% concordance with the serology, 12% discordance, 18% disagreement between ELISPOT or Quantiferon-CMV and the serology, and 24% gray areas when one or both tests resulted in weak positives. None of the CMV-seronegative subjects showed detectable responses in the ELISPOT or the Quantiferon-CMV test. In transplant recipients, both the ELISPOT and Quantiferon-CMV assays positively correlated with each other and negatively correlated with CMV DNAemia in a significant way ( P < 0.05). During the antiviral prophylaxis, all 20 D + /R − KTRs we examined displayed undetectable Quantiferon-CMV and ELISPOT results, and there was no evidence of CMV seroconversion. The receiving operator curve (ROC) statistical analysis revealed similar specificities and sensitivities in predicting detectable viremia (areas under the curve [AUC], 0.66 and 0.62 for Quantiferon-CMV and ELISPOT, respectively). ELISPOT and Quantiferon-CMV values of >150 spots/200,000 peripheral blood mononuclear cells (PBMCs) and >1 to 6 IU gamma interferon (IFN-γ) were associated with protection from CMV infection (odds ratios [OR], 5 and 8.75, respectively). In transplant recipients, the two tests displayed similar abilities for predicting CMV infection. Both the ELISPOT and Quantiferon-CMV assays require several ameliorations to avoid false-negative results.